

Opioids

Guillermo Burillo-Putze
Oscar Miro

REFERENCES

1. <http://www.samhsa.gov/data/2k13/DAWN2k11ED/DAWN2k11ED.htm> (U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality Drug Abuse Warning Network, 2011: National estimates of drug-related emergency department visits.) Accessed July 24, 2014.
2. Madadi P, Ross CJ, Hayden MR, et al: Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breast feeding: a case-control study. *Clin Pharmacol Ther* 85: 31, 2009. [PMID: 18719619]
3. Mowry JB, Spyker DA, Cantilena LR, McMillan N, Ford M: 2013 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st Annual Report. *Clin Toxicol (Phila)* 52:1032, 2014. [PMID: 25559822]
4. Boyer EW: Management of opioid analgesic overdose. *N Engl J Med* 367: 146, 2012. [PMID: 22784117]
5. Jones CM, Paulozzi LJ, Mack KA: Sources of prescription opioid pain relievers by frequency of past-year nonmedical use: United States, 2008-2011. *JAMA Intern Med* 174: 802, 2014. [PMID: 24589763]
6. Sporer KA: Acute heroin overdose. *Ann Intern Med* 130: 584, 1999. [PMID: 10189329]
7. Mell HK, Szajajkyrce MD: Clinical images in medical toxicology: heroin overdose with non-cardiogenic pulmonary edema. *Clin Toxicol (Phila)* 44: 399, 2006. [PMID: 16809144]
8. Sterrett C, Brownfield J, Korn CS, et al: Patterns of presentation in heroin overdose resulting in pulmonary edema. *Am J Emerg Med* 21: 32, 2003. [PMID: 12563576]
9. Das PK, Warkentin DL, Hewko R, Forrest DL: Serotonin syndrome after concomitant treatment with linezolid and meperidine. *Clin Infect Dis* 46: 264, 2008. [PMID: 18171260]
10. Reeves RR, Burke RS: Tramadol: basic pharmacology and emerging concepts. *Drugs Today (Barc)* 44: 827, 2008. [PMID: 19180260]
11. Hoffman JR, Schriger DL, Luo JS: The empiric use of naloxone in patients with altered mental status: a reappraisal. *Ann Emerg Med* 20: 246, 1991. [PMID: 1996818]
12. O'Malley GF, Seifert S, Heard K, et al: Olanzapine overdose mimicking opioid intoxication. *Ann Emerg Med* 34: 279, 1999. [PMID: 10424936]
13. Moeller KE, Lee KC, Kissack JC: Urine drug screening: practical guide for clinicians. *Mayo Clin Proc* 83: 66, 2008. Erratum in: *Mayo Clin Proc* 83: 851, 2008. [PMID: 18174009]
14. Schneir AB, Vadeboncoeur TF, Offerman SR, et al: Massive OxyContin ingestion refractory naloxone. *Ann Emerg Med* 40: 425, 2002. [PMID: 12239500]
15. Weber JM, Tataris KL, Hoffman JD, Aks SE, Mycyk MB: Can nebulized naloxone be used safely and effectively by emergency medical services for suspected opioid overdose? *Prehosp Emerg Care* 16: 289, 2012. [PMID: 22191727]
16. Baumann BM, Patterson RA, Parone DA, et al: Use and efficacy of nebulized naloxone in patients with suspected opioid intoxication. *Am J Emerg Med* 31: 585, 2013. [PMID: 23347721]
17. Tataris KL, Weber JM, Stein-Spencer K, Aks SE: The effect of prehospital nebulized naloxone on suspected heroin-induced bronchospasm. *Am J Emerg Med* 31: 717, 2013. [PMID: 23380114]
18. Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A: Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. *Ther Drug Monit* 30: 490, 2008. [PMID: 18641540]
19. Ashton H, Hassan Z: Best evidence topic report. Intranasal naloxone in suspected opioid overdose. *Emerg Med J* 23: 221, 2006. [PMID: 16498165]
20. Doe-Simkins M, Walley AY, Epstein A, Moyer P: Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. *Am J Public Health* 99: 788, 2009. [PMID: 19363214]
21. Clarke SF, Dargan PI, Jones AL: Naloxone in opioid poisoning: walking the tightrope. *Emerg Med J* 22: 612, 2005. [PMID: 16113176]
22. Wermeling DP: Review of naloxone safety for opioid overdoses: practical considerations for new technology and expanded public access. *Ther Adv Drug Saf* 6:20, 2015. [PMID: 25642320]
23. Schug SA, Zeich D, Grond S: Adverse effects of systemic opioid analgesics. *Drug Saf* 7: 200, 1992. [PMID: 1354445]
24. Aghabikloot A, Hassanian-Moghaddam H, Zamani N, et al: Effectiveness of naltrexone in the prevention of delayed respiratory arrest in opioid-naïve methadone-intoxicated patients. *Biomed Res Int* 2013: 903172, 2013. [PMID: 240898691]
25. Christenson J, Etherington J, Grafstein E, et al: Early discharge of patients with presumed opioid overdose: development of a clinical prediction rule. *Acad Emerg Med* 7: 1110, 2000. [PMID: 11015242]
26. Sporer KA: Buprenorphine: a primer for emergency physicians. *Ann Emerg Med* 43: 580, 2004. [PMID: 15111917]
27. Hayes BD, Klein-Schwartz W, Doyon S: Toxicity of buprenorphine overdose in children. *Pediatrics* 121: 3782, 2008. [PMID: 18381506]
28. Butler B, Rubin G, Lawrence A, Batey R, Bell J: Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. *Drug Alcohol Rev* 30: 173, 2011. [PMID: 21355903]
29. Center for Disease Control and Prevention (CDC): Vital signs: risk for overdose from methadone used for pain relief—United States, 1999-2010. *MMWR Morb Mortal Wkly Rep* 61: 493, 2012. [PMID: 22763888]
30. Kapur BM, Hutson JR, Chibber T, Luk A, Selby P: Methadone: a review of drug-drug and pathophysiological interactions. *Crit Rev Clin Lab Sci* 48: 171, 2011. [PMID: 22035341]
31. Arora A, Williams K: Problem based review: the patient taking methadone. *Acute Med* 12: 51, 2013. [PMID: 23539377]
32. Martin JA, Campbell A, Killip T, et al: QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. *J Addict Dis* 30: 283, 2011. [PMID: 22026519]
33. Shadnia S, Rahimi M, Hassanian-Moghaddam H, Soltaninejad K, Noroozi A: Methadone toxicity: comparing tablet and syrup formulations during a decade in an academic poison center of Iran. *Clin Toxicol (Phila)* 51: 777, 2013. [PMID: 23972442]
34. Barkin RL, Barkin SJ, Barkin DS: Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. *Am J Ther* 13: 534, 2006. [PMID: 17122535]
35. Stork CM, Pedd JT, Fine K, Hoffman RS: Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate—a case report. *J Toxicol Clin Toxicol* 33: 179, 1995. [PMID: 7897759]
36. Hantson P, Evenepoel M, Ziade D, Hassoun A, Mahieu P: Adverse cardiac manifestations following dextropropoxyphene overdose: can naloxone be helpful? *Ann Emerg Med* 25: 263, 1995. [PMID: 7832361]
37. Spiller HA, Gormann SE, Villaloboa D, et al: Prospective multicenter evaluation of tramadol exposure. *J Toxicol Clin Toxicol* 35: 361, 1997. [PMID: 9204095]
38. Shadnia S, Soltaninejad K, Heydari K, Sasanian F, Abdollahi M: Tramadol intoxication: a review of 114 cases. *Hum Exp Toxicol* 27: 201, 2008. [PMID: 18650251]
39. Hassanian-Moghaddam H, Farajidana H, Sarjami S, Owliaey H: Tramadol-induced apnea. *Am J Emerg Med* 31: 26, 2013. [PMID: 22809771]
40. Tashakori A, Afshari R: Tramadol overdose as a cause of serotonin syndrome: a case series. *Clin Toxicol (Phila)* 48: 337, 2010. [PMID: 20367390]
41. Taghaddosinejad F, Mehrpour O, Afshari R, et al: Factors related to seizure in tramadol poisoning and its blood concentration. *J Med Toxicol* 7: 183, 2011. [PMID: 21735309]
42. Shadnia S, Brent J, Mousavi-Fatemi K, Hafezi P, Soltaninejad K: Recurrent seizures in tramadol intoxication: implications for therapy based on 100 patients. *Basic Clin Pharmacol* 111: 133, 2012. [PMID: 22364547]
43. WHO Expert Committee on Drug Dependence: *World Health Organ Tech Rep Ser* 942: 1, 2006. [PMID: 17373571]
44. Challoner KR, McCarron MM, Newton EJ: Pentazocine (Talwin) intoxications: report of 57 cases. *J Emerg Med* 8: 67, 1990. [PMID: 2351801]
45. Centers for Disease Control and Prevention (CDC): Nonpharmaceutical fentanyl-related deaths—multiple states, April 2005–March 2007. *MMWR Morb Mortal Wkly Rep* 57: 793, 2008. [PMID: 18650786]
46. Burns RS, LeWitt PA, Ebert MH, et al: The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). *N Engl J Med* 312: 1418, 1985. [PMID: 2581135]
47. Skowronek R, Celinski R, Chowaniec C: "Crocodile"—new dangerous designer drug of abuse from the East. *Clin Toxicol (Phila)* 50: 269, 2012. [PMID: 22385107]
48. Ulbricht C, Costa D, Dao J, et al: An evidence-based systematic review of kratom (*Mitragyna speciosa*) by the Natural Standard Research Collaboration. *J Diet Suppl* 10: 152, 2013. [PMID: 23725528]
49. Hassan Z, Muzaaimi M, Navaratnam V, et al: From Kratom to mitragynine and its derivatives: physiological and behavioural effects relates to its use, abuse, and addiction. *Neurosci Biobehav Rev* 37: 138, 2013. [PMID: 23206666]
50. Singh D, Muller CP, Vicknasingam BK: Kratom (*Mitragyna speciosa*) dependent, withdrawal symptoms and craving in regular users. *Drug Alcohol Depend* 139: 132, 2014. [PMID: 24698080]
51. Neerman MF, Frost RE, Dekker J: A drug fatality involving kratom. *J Forensic Sci* 58 (Suppl 1): S278, 2013. [PMID: 23082895]
52. Kronstrand R, Roman M, Thelander G, Eriksson A: Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend krypton. *J Anal Toxicol* 35: 242, 2011. [PMID: 21513619]
53. Prozialeck WC, Jivan JK, Andurkar SV: Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. *J Am Osteopath Assoc* 112: 792, 2012. [PMID: 23212430]
54. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH: Self-treatment of opioid withdrawal using kratom (*Mitragyna speciosa* korth). *Addiction* 103: 1048, 2008. [PMID: 18482427]
55. Kosten TR, O'Connor PG: Management of drug and alcohol withdrawal. *N Engl J Med* 348: 1786, 2003. [PMID: 12724485]
56. Handelsman L, Cochrane KJ, Aronson MJ, et al: Two new rating scales of opiate withdrawal. *Am J Drug Alcohol Abuse* 13: 293, 1987. [PMID: 3687892]
57. Gowing L, Farrell M, Ali R, White JM: Alpha 2-adrenergic agonists for the management of opioid withdrawal. *Cochrane Database Syst Rev* 3: CD002025, 2014. [PMID: 24683051]
58. Pinkofsky HB, Hahn AM, Campbell FA, et al: Reduction of opioid-withdrawal symptoms with quetiapine. *J Clin Psychiatry* 66: 1285, 2005. [PMID: 16259542]
59. Praveen KT, Law F, O'Shea J, Melichar J: Opioid dependence. *Am Fam Physician* 86: 565, 2012. [PMID: 23062049]
60. Gowing L, Ali R, White JM: Buprenorphine for the management of opioid withdrawal. *Cochrane Database Syst Rev* 3: CD002025, 2009. [PMID: 19588330]

USEFUL WEB RESOURCES

American Academy of Clinical Toxicology—<http://www.clintox.org/index.cfm>
American Association of Poison Control Centers—<http://www.aapcc.org/DNN/>
Asia Pacific Association of Medical Toxicology—<http://www.asiatox.org/>

Drug Abuse Warning Network—<http://dawninfo.samhsa.gov/>
European Association of Poisons Centres and Clinical Toxicologists—<http://www.eapcct.org/>
South Asian Clinical Toxicology Research Collaboration—<http://www.sactrc.org/>